MORF

Morphic Holding, Inc. (MORF) | Rumor.io

Morphic Holding

MORF

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MORF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Dec 1

The community has been actively discussing the potential of $MORF, with some predicting a 320x increase in value.
$MORF is being referred to as a "meme coin" and is gaining traction on Phantom, with some users expressing excitement about its prospects.
The company's CTO is being highlighted as a key factor in $MORF's potential, with some users speculating about the project's market capitalization and future growth.

Generated by AI

Sentiment

Of the messages about MORF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	67% -24.42
Bearish	—	—	—	33% +24.42

Bullish· Jul 8

$MORF was acquired by $LLY for $57 per share, a 78% premium.
The stock price of $MORF skyrocketed by 75.41% in a single day, driven by promising advancements in oral integrin therapies.
$MORF is expected to have significant future upside, with excellent results and fundamentals supporting the stock.

Bearish· Sep 25

$MORF's YTD gains have evaporated, and the stock has been heavily sold down.
The company's drug underperformed a rival from $TAK, leading to a significant loss in value.
$MORF's stock price has been downgraded, and the company's price target has been reduced, contributing to the bearish sentiment.

Generated by AI

Topics

Of the messages about MORF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0.53%
Announcements	100%	100%	100%	99.47%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Jul 8

Eli Lilly has agreed to buy Morphic Holding, Inc. for $3.2 billion in a deal that bolsters the drugmaker's immunology pipeline.
The acquisition price is $57 per share in cash, a 78% premium to Morphic Holding's previous trading price.
The deal aims to improve outcomes for patients with inflammatory bowel disease by expanding Eli Lilly's immunology pipeline with oral integrin therapies.

Generated by AI

Community

Of the messages about MORF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	98.82%	57.6%
Newcomers	100%	100%	1.18%	42.4%

Regulars· Sep 25

The regulars are focused on the upcoming P2a UC data and its potential impact on the stock price, with some anticipating positive results.
The sell-side is expected to provide defense for the stock, but this may not be enough to prevent further price declines.
The biotech's stock price is being compared to other companies, with some suggesting that Morphic's stock could trade at a much lower valuation, potentially below cash levels.

Newcomers· Sep 25

Newcomers are noticing similarities between MORF and APLS, with MORF trading like a 2.0 version of APLS.
Some newcomers are bringing up past controversies, including the company issuing $100M shares to a board member and the recent underperformance of its ulcerative colitis drug.
The company's stock has lost about half its value over the past two days, with some newcomers setting a support level at $23 and expecting a potential drop to $10 if it falls below.

Generated by AI

Also Discussed

Investors talking about MORF also mention

#	Name	Attention
1	U.S. Physical Therapy, Inc.USPH	0%0
2	Protagonist Therapeutics, Inc.PTGX	0%new
3	Vir Biotechnology, Inc.VIR	0%+0
4	Immatics N.V.IMTX	0%0
5	White Mountains Insurance Group Ltd.WTM	0%0
6	Vincerx Pharma Inc.VINC	0%new
7	Pliant Therapeutics Inc.PLRX	0%0
8	Townsquare Media Inc.TSQ	0%new
9	CSGS - CSG Systems International, Inc.	——
10	International Bancshares Corp.IBOC	0%0

Morphic Holding, Inc.

Location

Social

What share of all stock conversation is about MORF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Dec 1

The community has been actively discussing the potential of $MORF, with some predicting a 320x increase in value.
$MORF is being referred to as a "meme coin" and is gaining traction on Phantom, with some users expressing excitement about its prospects.
The company's CTO is being highlighted as a key factor in $MORF's potential, with some users speculating about the project's market capitalization and future growth.

Generated by AI

Sentiment

Of the messages about MORF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	67% -24.42
Bearish	—	—	—	33% +24.42

Bullish· Jul 8

$MORF was acquired by $LLY for $57 per share, a 78% premium.
The stock price of $MORF skyrocketed by 75.41% in a single day, driven by promising advancements in oral integrin therapies.
$MORF is expected to have significant future upside, with excellent results and fundamentals supporting the stock.

Bearish· Sep 25

$MORF's YTD gains have evaporated, and the stock has been heavily sold down.
The company's drug underperformed a rival from $TAK, leading to a significant loss in value.
$MORF's stock price has been downgraded, and the company's price target has been reduced, contributing to the bearish sentiment.

Generated by AI

Topics

Of the messages about MORF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0.53%
Announcements	100%	100%	100%	99.47%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Jul 8

Eli Lilly has agreed to buy Morphic Holding, Inc. for $3.2 billion in a deal that bolsters the drugmaker's immunology pipeline.
The acquisition price is $57 per share in cash, a 78% premium to Morphic Holding's previous trading price.
The deal aims to improve outcomes for patients with inflammatory bowel disease by expanding Eli Lilly's immunology pipeline with oral integrin therapies.

Generated by AI

Community

Of the messages about MORF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	98.82%	57.6%
Newcomers	100%	100%	1.18%	42.4%

Regulars· Sep 25

The regulars are focused on the upcoming P2a UC data and its potential impact on the stock price, with some anticipating positive results.
The sell-side is expected to provide defense for the stock, but this may not be enough to prevent further price declines.
The biotech's stock price is being compared to other companies, with some suggesting that Morphic's stock could trade at a much lower valuation, potentially below cash levels.

Newcomers· Sep 25

Newcomers are noticing similarities between MORF and APLS, with MORF trading like a 2.0 version of APLS.
Some newcomers are bringing up past controversies, including the company issuing $100M shares to a board member and the recent underperformance of its ulcerative colitis drug.
The company's stock has lost about half its value over the past two days, with some newcomers setting a support level at $23 and expecting a potential drop to $10 if it falls below.

Generated by AI

Morphic Holding

Social

Dec 1

Sentiment

Bullish· Jul 8

Bearish· Sep 25

Topics

Jul 8

Community

Regulars· Sep 25

Newcomers· Sep 25

Also Discussed

Morphic Holding, Inc.

Company Information

Location

Also Discussed

Social

Dec 1

Sentiment

Bullish· Jul 8

Bearish· Sep 25

Topics

Jul 8

Community

Regulars· Sep 25

Newcomers· Sep 25